Denosumab

The FDA approved the first two denosumab biosimilars.

The FDA has added a boxed warning for denosumab to advise patients with advanced chronic kidney disease of an increased risk for severe hypocalcemia, according to an FDA drug safety communication.

SAN DIEGO — Romosozumab is superior to denosumab for increasing bone mineral density in the spine at 12 months among chronic glucocorticoid users with osteoporosis at high fracture risk, according to data presented at ACR Convergence 2023.

Researchers identified an association between industry payments to physicians and nonrecommended and low-value drugs in certain clinical scenarios, according to study results published in The BMJ.

SANTA FE, N.M. — In this video exclusive, Michael R. McClung, MD, discusses strategies for drug holidays and transitions between osteoporosis therapies.

Adults with overweight or obesity, but not type 2 diabetes, lost 14.9% of their body weight after 46 weeks of receiving BI 456906, a novel glucagon/GLP-1 receptor agonist, during a phase 2 clinical trial, according to a press release.

Postmenopausal women with osteoporosis who use denosumab as a first-line therapy have lowers risk for fractures compared with women who use alendronate, according to an industry press release.

A new clinical practice guideline from the Endocrine Society recommends treatment with IV bisphosphonates or denosumab in addition to adequate hydration for adults with moderate hypercalcemia of malignancy.

PHILADELPHIA — Denosumab successfully induces structural modifications patients with active erosive hand osteoarthritis, according to data presented at ACR Convergence 2022.

During the past 20 years, Endocrine Today has covered the latest advancements surrounding osteoporosis care. For its 20th year, the publication is taking a look back.